Molecular pathogenesis of MLL-AF4 leukemias
MLL-AF4 白血病的分子发病机制
基本信息
- 批准号:8635305
- 负责人:
- 金额:$ 34.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-01 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:11q23Acute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute leukemiaAddressCell LineCell MaintenanceCell SurvivalCell physiologyCellsChromosomal translocationCommitDNA Sequence RearrangementDevelopmentDiagnosisDiseaseEvaluationExcisionGene ExpressionGoalsGrowth and Development functionHematopoiesisHematopoieticHematopoietic stem cellsHistone H3HistonesHumanIn VitroInfant LeukemiaLightLymphoblastic LeukemiaLymphoidLysineMLL geneMLL-AF9MLLT2 geneMediatingMethylationModelingModificationMolecularMolecular ProfilingMusPathogenesisPatientsReportingRoleSamplingTherapeuticUrsidae Familycell typechromatin modificationgenome-widehistone methyltransferasein vivoleukemiamouse modelnovel therapeutic interventionoutcome forecastprogenitorprogramspublic health relevancerecombinaseresearch studyretroviral transductionsmall hairpin RNAtherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Acute leukemias that bear chromosomal translocations at 11q23 possess rearrangements of the Mixed Lineage Leukemia gene (MLL, HRX, ALL-1). More than 40 different MLL translocations have been reported, but the t(4;11) (MLL-AF4) is particularly common in leukemias diagnosed as ALL or mixed-lineage leukemia. Patients with MLL-AF4 leukemias have a poor prognosis. This is particularly true for infant leukemia where approximately 80% of cases will harbor rearrangement of the MLL gene. We have recently developed a conditional mouse model of Mll-AF4 ALL that recapitulates the gene expression profiles and histone methylation profiles of human MLL-AF4 ALL. Experiments described in this proposal will build upon these previous studies and characterize leukemia development with a particular focus on histone methylation. We will determine which cell types are permissive for Mll-AF4 leukemia development including hematopoietic stem cells (HSC) and early lymphoid committed cells. We will also determine if MLL-AF4 leukemia cell survival is dependent upon the histone methyltransferase Dot1L. These studies will provide a highly detailed characterization of the cells of origin of Mll-AF4 ALL, and begin to determine if histone methyltransferases are potential therapeutic targets in this disease.
描述(由申请方提供):在11 q23处携带染色体易位的急性白血病具有混合谱系白血病基因(MLL、HRX、ALL-1)重排。已经报道了超过40种不同的MLL易位,但是t(4;11)(MLL-AF 4)在诊断为ALL或混合谱系白血病的白血病中特别常见。MLL-AF 4白血病患者预后不良。这对于婴儿白血病尤其如此,其中大约80%的病例将具有MLL基因重排。我们最近开发了一种MLL-AF 4 ALL的条件性小鼠模型,该模型概括了人MLL-AF 4 ALL的基因表达谱和组蛋白甲基化谱。本提案中描述的实验将建立在这些先前的研究基础上,并以组蛋白甲基化为特别重点来表征白血病的发展。我们将确定哪些细胞类型允许MII-AF 4白血病发展,包括造血干细胞(HSC)和早期淋巴定向细胞。我们还将确定MLL-AF 4白血病细胞的存活是否依赖于组蛋白甲基转移酶Dot 1 L。这些研究将提供MII-AF 4 ALL起源细胞的高度详细的表征,并开始确定组蛋白甲基转移酶是否是该疾病的潜在治疗靶点。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The role of DOT1L in the maintenance of leukemia gene expression.
- DOI:10.1016/j.gde.2016.03.015
- 发表时间:2016-02
- 期刊:
- 影响因子:4
- 作者:Xi Wang;Chun-Wei Chen;S. Armstrong
- 通讯作者:Xi Wang;Chun-Wei Chen;S. Armstrong
Chromatin-modifying enzymes as modulators of reprogramming.
- DOI:10.1038/nature10953
- 发表时间:2012-03-04
- 期刊:
- 影响因子:64.8
- 作者:Onder, Tamer T.;Kara, Nergis;Cherry, Anne;Sinha, Amit U.;Zhu, Nan;Bernt, Kathrin M.;Cahan, Patrick;Mancarci, B. Ogan;Unternaehrer, Juli;Gupta, Piyush B.;Lander, Eric S.;Armstrong, Scott A.;Daley, George Q.
- 通讯作者:Daley, George Q.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT A ARMSTRONG其他文献
SCOTT A ARMSTRONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT A ARMSTRONG', 18)}}的其他基金
The Center for Therapeutic Targeting of EWS-oncoproteins
EWS癌蛋白治疗靶向中心
- 批准号:
10671815 - 财政年份:2022
- 资助金额:
$ 34.52万 - 项目类别:
The Center for Therapeutic Targeting of EWS-oncoproteins
EWS癌蛋白治疗靶向中心
- 批准号:
10382013 - 财政年份:2021
- 资助金额:
$ 34.52万 - 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
- 批准号:
10184546 - 财政年份:2021
- 资助金额:
$ 34.52万 - 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
- 批准号:
10640846 - 财政年份:2021
- 资助金额:
$ 34.52万 - 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
- 批准号:
10388249 - 财政年份:2021
- 资助金额:
$ 34.52万 - 项目类别:
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
靶向 DOT1L 降解 MLL 重排白血病
- 批准号:
10411945 - 财政年份:2012
- 资助金额:
$ 34.52万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 34.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 34.52万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 34.52万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 34.52万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 34.52万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 34.52万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 34.52万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 34.52万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 34.52万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 34.52万 - 项目类别:














{{item.name}}会员




